IL252252A0 - Transducible bridged urea analogs as sirtuin modulators - Google Patents
Transducible bridged urea analogs as sirtuin modulatorsInfo
- Publication number
- IL252252A0 IL252252A0 IL252252A IL25225217A IL252252A0 IL 252252 A0 IL252252 A0 IL 252252A0 IL 252252 A IL252252 A IL 252252A IL 25225217 A IL25225217 A IL 25225217A IL 252252 A0 IL252252 A0 IL 252252A0
- Authority
- IL
- Israel
- Prior art keywords
- substituted bridged
- sirtuin modulators
- urea analogs
- bridged urea
- analogs
- Prior art date
Links
- 102000011990 Sirtuin Human genes 0.000 title 1
- 108050002485 Sirtuin Proteins 0.000 title 1
- 150000003672 ureas Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462081916P | 2014-11-19 | 2014-11-19 | |
| PCT/IB2015/058978 WO2016079710A1 (en) | 2014-11-19 | 2015-11-19 | Substituted bridged urea analogs as sirtuin modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL252252A0 true IL252252A0 (en) | 2017-07-31 |
Family
ID=54705247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL252252A IL252252A0 (en) | 2014-11-19 | 2017-05-11 | Transducible bridged urea analogs as sirtuin modulators |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20170355705A1 (OSRAM) |
| EP (4) | EP3221317B1 (OSRAM) |
| JP (4) | JP2017534663A (OSRAM) |
| KR (4) | KR20170087907A (OSRAM) |
| CN (4) | CN107207520A (OSRAM) |
| AU (4) | AU2015348944A1 (OSRAM) |
| BR (4) | BR112017010602A2 (OSRAM) |
| CA (4) | CA2968032A1 (OSRAM) |
| CL (1) | CL2017001275A1 (OSRAM) |
| CO (1) | CO2017004994A2 (OSRAM) |
| CR (1) | CR20170209A (OSRAM) |
| DO (1) | DOP2017000123A (OSRAM) |
| EA (1) | EA201791074A1 (OSRAM) |
| ES (1) | ES2823748T3 (OSRAM) |
| IL (1) | IL252252A0 (OSRAM) |
| MX (1) | MX2017006658A (OSRAM) |
| PE (1) | PE20171257A1 (OSRAM) |
| PH (1) | PH12017500913A1 (OSRAM) |
| RU (3) | RU2017120855A (OSRAM) |
| SG (1) | SG11201703824QA (OSRAM) |
| WO (4) | WO2016079712A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016086088A2 (en) | 2014-11-25 | 2016-06-02 | Northwestern University | Wound healing through sirt1 overexpression |
| CN108329388A (zh) * | 2018-01-18 | 2018-07-27 | 天津市湖滨盘古基因科学发展有限公司 | 一种人的沉默配型信息调节蛋白突变蛋白及其应用 |
| CN108707150B (zh) * | 2018-05-14 | 2021-04-16 | 江苏惠利生物科技有限公司 | 一种咪唑并吡嗪医药中间体的制备方法 |
| CN108395436B (zh) * | 2018-05-14 | 2021-01-12 | 鹤壁市人民医院 | 一种咪唑并吡嗪医药中间体的制备方法 |
| CN110478339A (zh) * | 2019-08-12 | 2019-11-22 | 昆明理工大学 | 紫铆因在制备靶向恢复突变p53构象药物中的应用 |
| EP4025566A1 (de) * | 2019-09-02 | 2022-07-13 | Merck Patent GmbH | Materialien für organische elektrolumineszenzvorrichtungen |
| BR112022009649A2 (pt) * | 2019-11-19 | 2022-08-16 | Lupin Ltd | Processo, intermediários e métodos para preparar compostos de cromano |
| FI4090654T3 (fi) * | 2020-01-17 | 2025-09-30 | Lupin Ltd | Menetelmiä, prosesseja ja välituotteita kromaaniyhdisteiden valmistamiseksi |
| CN114890955A (zh) * | 2022-06-23 | 2022-08-12 | 江西瑞威尔生物科技有限公司 | 一种n取代吗啉类有机化合物的制备工艺 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| WO2006094210A2 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Tetrahydroquinoxalinone sirtuin modulators |
| UA108596C2 (xx) | 2007-11-09 | 2015-05-25 | Інгібітори пептиддеформілази | |
| CA2779303A1 (en) * | 2009-10-29 | 2011-05-19 | Sirtris Pharmaceuticals, Inc. | Bicyclic pyridines and analogs as sirtuin modulators |
| AU2012352442A1 (en) * | 2011-12-12 | 2014-07-03 | Smb Innovation Aps | Novel heterocyclic compounds useful in sirtuin binding and modulation |
| WO2014186313A1 (en) * | 2013-05-13 | 2014-11-20 | Glaxosmithkline Llc | Substituted bridged urea analogs as sirtuin modulators |
-
2015
- 2015-11-19 RU RU2017120855A patent/RU2017120855A/ru unknown
- 2015-11-19 WO PCT/IB2015/058981 patent/WO2016079712A1/en not_active Ceased
- 2015-11-19 WO PCT/IB2015/058978 patent/WO2016079710A1/en not_active Ceased
- 2015-11-19 CA CA2968032A patent/CA2968032A1/en not_active Abandoned
- 2015-11-19 US US15/527,440 patent/US20170355705A1/en not_active Abandoned
- 2015-11-19 CR CR20170209A patent/CR20170209A/es unknown
- 2015-11-19 KR KR1020177016279A patent/KR20170087907A/ko not_active Withdrawn
- 2015-11-19 SG SG11201703824QA patent/SG11201703824QA/en unknown
- 2015-11-19 BR BR112017010602A patent/BR112017010602A2/pt not_active Application Discontinuation
- 2015-11-19 EP EP15801271.6A patent/EP3221317B1/en active Active
- 2015-11-19 BR BR112017010599A patent/BR112017010599A2/pt not_active Application Discontinuation
- 2015-11-19 JP JP2017526875A patent/JP2017534663A/ja not_active Withdrawn
- 2015-11-19 CN CN201580073769.9A patent/CN107207520A/zh active Pending
- 2015-11-19 AU AU2015348944A patent/AU2015348944A1/en not_active Abandoned
- 2015-11-19 JP JP2017526950A patent/JP2017534664A/ja active Pending
- 2015-11-19 WO PCT/IB2015/058980 patent/WO2016079711A1/en not_active Ceased
- 2015-11-19 BR BR112017010601A patent/BR112017010601A2/pt not_active Application Discontinuation
- 2015-11-19 AU AU2015348942A patent/AU2015348942B2/en not_active Ceased
- 2015-11-19 ES ES15801271T patent/ES2823748T3/es active Active
- 2015-11-19 KR KR1020177016280A patent/KR20170083135A/ko not_active Withdrawn
- 2015-11-19 EP EP15801270.8A patent/EP3221316A1/en not_active Withdrawn
- 2015-11-19 RU RU2017120857A patent/RU2017120857A/ru unknown
- 2015-11-19 CA CA2968030A patent/CA2968030A1/en not_active Abandoned
- 2015-11-19 US US15/527,851 patent/US20190048016A1/en not_active Abandoned
- 2015-11-19 AU AU2015348941A patent/AU2015348941A1/en not_active Abandoned
- 2015-11-19 CA CA2968027A patent/CA2968027A1/en not_active Abandoned
- 2015-11-19 MX MX2017006658A patent/MX2017006658A/es unknown
- 2015-11-19 CN CN201580073897.3A patent/CN107207509B/zh not_active Expired - Fee Related
- 2015-11-19 US US15/527,941 patent/US20180319810A1/en not_active Abandoned
- 2015-11-19 BR BR112017010595-0A patent/BR112017010595A2/pt not_active Application Discontinuation
- 2015-11-19 AU AU2015348943A patent/AU2015348943A1/en not_active Abandoned
- 2015-11-19 WO PCT/IB2015/058977 patent/WO2016079709A1/en not_active Ceased
- 2015-11-19 JP JP2017526852A patent/JP6806679B2/ja not_active Expired - Fee Related
- 2015-11-19 PE PE2017000883A patent/PE20171257A1/es not_active Application Discontinuation
- 2015-11-19 CA CA2968029A patent/CA2968029A1/en not_active Abandoned
- 2015-11-19 CN CN201580073782.4A patent/CN107207521A/zh active Pending
- 2015-11-19 EP EP15804601.1A patent/EP3220918A1/en not_active Withdrawn
- 2015-11-19 US US15/527,581 patent/US10072011B2/en not_active Expired - Fee Related
- 2015-11-19 KR KR1020177016278A patent/KR20170083134A/ko not_active Withdrawn
- 2015-11-19 KR KR1020177016277A patent/KR20170083133A/ko not_active Withdrawn
- 2015-11-19 EP EP15816522.5A patent/EP3221322A1/en not_active Withdrawn
- 2015-11-19 RU RU2017120858A patent/RU2017120858A/ru unknown
- 2015-11-19 EA EA201791074A patent/EA201791074A1/ru unknown
- 2015-11-19 CN CN201580073311.3A patent/CN107108627A/zh active Pending
- 2015-11-19 JP JP2017526965A patent/JP2017534665A/ja active Pending
-
2017
- 2017-05-11 IL IL252252A patent/IL252252A0/en unknown
- 2017-05-17 PH PH12017500913A patent/PH12017500913A1/en unknown
- 2017-05-18 DO DO2017000123A patent/DOP2017000123A/es unknown
- 2017-05-18 CL CL2017001275A patent/CL2017001275A1/es unknown
- 2017-05-19 CO CONC2017/0004994A patent/CO2017004994A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259421B (en) | ror - gamma modulators | |
| DK3394033T3 (da) | Heterocykliske forbindelser som immunmodulatorer | |
| IL252554A0 (en) | A history of mutated 2-anilinopyrimidines as egfr modulators | |
| MA43382A (fr) | Modulateurs des récepteurs des chimiokines | |
| TWI561516B (en) | Substituted dihydroisoquinolinone compounds | |
| DK3294713T3 (da) | Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer | |
| IL252252A0 (en) | Transducible bridged urea analogs as sirtuin modulators | |
| DK3131902T3 (da) | Forbindelser som ROR-gamma-modulatorer | |
| EP3221312A4 (en) | Substituted bridged urea analogs as sirtuin modulators | |
| IL256432A (en) | 6-amino-quinoline-3-carbonitrils as cot modulators | |
| ZA201605332B (en) | Trpa1 modulators | |
| GB201405991D0 (en) | Novel compounds | |
| PL3303293T3 (pl) | Modulatory ROR-gamma | |
| PL3303290T3 (pl) | Modulatory ROR-gamma | |
| PL3303291T3 (pl) | Modulatory ROR-gamma | |
| IL249267A0 (en) | Materials containing carbonitrile and their use for selective modulation of the androgen receptor | |
| IL253096A0 (en) | New calcium modulators | |
| GB201404002D0 (en) | Novel compounds | |
| PL3319942T3 (pl) | MODULATORY ROR-GAMMA (RORγ) | |
| DK3145916T3 (da) | Imidazolderivater som formylpeptidreceptormodulatorer | |
| PL2940229T3 (pl) | Urządzenie do mocowania elementów drążonych, przykładowo na fasadach | |
| GB201712632D0 (en) | Anthelmintic compounds | |
| GB201406022D0 (en) | Outrigger pad carrier | |
| HK1240212A1 (en) | Substituted bridged urea analogs as sirtuin modulators | |
| GB201512714D0 (en) | Receptor modulator compounds |